TScan Therapeutics, Inc. (TCRX)

Over the past six months, TScan Therapeutics' stock (TCRX) has declined by 58.02%, from $2.43 to $1.02 per share. Key events include positive updated data from the ALLOHA™ Phase 1 heme trial presented in December 2025, a strategic decision to prioritize the hematologic malignancy program while pausing enrollment in the solid tumor TCR-T study, and analyst ratings with a consensus of "Buy" or "Strong Buy" but MarketBeat reports a consensus rating of "Hold".

Historical data suggests some seasonality in TScan Therapeutics, Inc. (TCRX) stock performance. May has shown the highest probability of a positive return at 75.00%, while December has the lowest at 0.00%. February also shows a lower probability of positive returns at 40.00%.

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell receptor (TCR) engineered T cell therapies (TCR-T) for cancer patients. The company utilizes its TargetScan™ platform to identify novel antigens and aims to build an ImmunoBank of TCRs. Its major product candidates, TSC-100 and TSC-101, are in Phase I clinical trials for hematologic malignancies. TScan is also developing multiplexed TCR-T therapy candidates for solid tumors and vaccines for infectious diseases and has collaborations with Novartis and Amgen.

TScan Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States, and focuses on developing T-cell receptor-engineered T cell therapies for cancer patients in the United States.

TScan Therapeutics' brand reputation has been influenced by positive clinical developments and strategic corporate decisions. Positive data from the ALLOHA™ Phase 1 heme trial for TSC-101 has bolstered its scientific and clinical reputation. However, the decision to prioritize the hematologic malignancy program and pause enrollment in the solid tumor TCR-T study, along with a 30% reduction in personnel, has created a negative outlook for the stock.

TScan Therapeutics, Inc. (TCRX) has a diverse ownership structure comprising institutional, retail, and individual investors. Approximately 10.34% of the company's stock is owned by Institutional Investors, 20.34% by Insiders, and 69.32% by Public Companies and Individual Investors. Major institutional shareholders include Lynx1 Capital Management LP, Bvf Inc/il, Baker Bros. Advisors Lp, Vanguard Group Inc, BlackRock, Inc., Propel Bio Management, LLC, Standard Life Aberdeen plc, Alphabet Inc., JPMorgan Chase & Co., Citadel Advisors LLC, and Goldman Sachs Group Inc.